Inozyme Pharma Inc (NASDAQ:INZY) has a beta value of 1.40 and has seen 1.41 million shares traded in the last trading session. The company, currently valued at $170.23M, closed the last trade at $2.65 per share which meant it gained $0.01 on the day or 0.38% during that session. The INZY stock price is -194.34% off its 52-week high price of $7.80 and 1.51% above the 52-week low of $2.61. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.41 million shares traded. The 3-month trading volume is 263.15K shares.

The consensus among analysts is that Inozyme Pharma Inc (INZY) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 6 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.38.

Inozyme Pharma Inc (NASDAQ:INZY) trade information

Sporting 0.38% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the INZY stock price touched $2.65 or saw a rise of 8.3%. Year-to-date, Inozyme Pharma Inc shares have moved -37.79%, while the 5-day performance has seen it change -5.69%. Over the past 30 days, the shares of Inozyme Pharma Inc (NASDAQ:INZY) have changed -44.56%. Short interest in the company has seen 3.23 million shares shorted with days to cover at 14.61.

Wall Street analysts have a consensus price target for the stock at $14, which means that the shares’ value could jump 81.07% from current levels. The projected low price target is $14.0 while the price target rests at a high of $16.0. In that case, then, we find that the current price level is -503.77% off the targeted high while a plunge would see the stock gain -428.3% from current levels.

Inozyme Pharma Inc (INZY) estimates and forecasts

Figures show that Inozyme Pharma Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -41.24% over the past 6 months, with this year growth rate of -16.06%, compared to 17.90% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -35.73% over the past 5 years. Earnings growth for 2024 is a modest -16.46% while over the next 5 years, the company’s earnings are expected to increase by 13.10%.

INZY Dividends

Inozyme Pharma Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Inozyme Pharma Inc (NASDAQ:INZY)’s Major holders

Insiders own 0.51% of the company shares, while shares held by institutions stand at 96.67% with a share float percentage of 97.16%. Investors are also buoyed by the number of investors in a company, with Inozyme Pharma Inc having a total of 127.0 institutions that hold shares in the company. The top two institutional holders are ADAGE CAPITAL PARTNERS GP, L.L.C. with over 5.73 million shares worth more than $25.55 million. As of 2024-06-30, ADAGE CAPITAL PARTNERS GP, L.L.C. held 9.2742% of shares outstanding.

The other major institutional holder is PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC, with the holding of over 4.49 million shares as of 2024-06-30. The firm’s total holdings are worth over $20.05 million and represent 7.2765% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Fidelity Select Portfolios – Biotechnology . As of Jun 30, 2024 , the former fund manager holds about 6.13% shares in the company for having 3.94 shares of worth $10.43 million while later fund manager owns 2.47 shares of worth $6.55 million as of Sep 30, 2024 , which makes it owner of about 3.85% of company’s outstanding stock.